

Resource Summary Report

Generated by [nidm-terms](#) on Jul 29, 2026

Variant Effect Predictor

RRID:SCR_007931

Type: Tool

Proper Citation

Variant Effect Predictor (RRID:SCR_007931)

Resource Information

URL: <http://www.ensembl.org/info/docs/tools/vep/index.html>

Proper Citation: Variant Effect Predictor (RRID:SCR_007931)

Description: Data analysis service to predict the functional consequences of known and unknown variants.

Abbreviations: VEP

Synonyms: VeIP

Resource Type: service resource, data analysis service, software resource, production service resource, analysis service resource

Keywords: perl, bio.tools

Resource Name: Variant Effect Predictor

Resource ID: SCR_007931

Alternate IDs: biotools:ensembl_variant_effect_predictor

Alternate URLs: https://bio.tools/ensembl_variant_effect_predictor

Record Creation Time: 20220129T080244+0000

Record Last Update: 20260729T044156+0000

Ratings and Alerts

No rating or validation information has been found for Variant Effect Predictor.

No alerts have been found for Variant Effect Predictor.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1871 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Cappadona C, et al. (2026) Multi-omics identifies oxidative stress, prothrombotic pathways, and lactoperoxidase variants as key factors in COVID-19 severity. EBioMedicine, 123, 106111.

Lazare S, et al. (2026) Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 135.

Hsu HC, et al. (2026) Expression of Bacillus in colorectal tissues is associated with improved cetuximab therapy for patients with metastatic colorectal cancer. Translational oncology, 63, 102575.

Bonamici L, et al. (2026) Characterization of Copy Number Variants in Hereditary Cancer Patients Through NGS Shows a Distinctive PALB2 Contribution to the Diagnostic Yield. Human mutation, 2026, 6601291.

Browne IM, et al. (2026) The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 148.

Teng CS, et al. (2026) Actomyosin contractility and a threshold of cadherin cell adhesion are required during tissue fusion. The Journal of cell biology, 225(1).

Umeda M, et al. (2025) Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia. medRxiv : the preprint server for health sciences.

Persaud N, et al. (2025) Clinical Significance of TERT Promoter Mutations in Neuroblastoma. JCO precision oncology, 9, e2500074.

Godinez-Zamora GF, et al. (2025) Contribution of next generation sequencing to the diagnosis of inborn errors of immunity in a pediatric cohort. Frontiers in immunology, 16, 1638544.

Honoré N, et al. (2025) Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(22), 4790.

Arenillas C, et al. (2025) Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes. Cancer discovery,

15(5), 1037.

Van Laethem JL, et al. (2025) CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. *Cell reports. Medicine*, 6(10), 102407.

Chauhan PS, et al. (2025) Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(1), 151.

Akatsuka H, et al. (2025) Molecular and genetic evidence for the role of AMBRA1 in suppressing S-phase entry and tumorigenesis. *iScience*, 28(8), 113054.

Pavan C, et al. (2025) PARKIN protein-deficient iPSC line (FINi006-A) from an early-onset Parkinson's disease female patient. *Stem cell research*, 87, 103795.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. *Cancer research communications*, 5(3), 476.

Khan N, et al. (2025) Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers. *Cancer discovery*, 15(9), 1927.

George SL, et al. (2025) Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States. *Cancer discovery*, 15(4), 717.

Li Y, et al. (2025) Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(12), 2495.

Lange LM, et al. (2025) The LRRK2 p.L1795F variant causes Parkinson's disease in the European population. *NPJ Parkinson's disease*, 11(1), 58.